Allen Robert D. III 4
4 · Invivyd, Inc. · Filed Feb 18, 2026
Research Summary
AI-generated summary of this filing
Invivyd (IVVD) CSO Robert D. Allen III Sells Shares
What Happened
- Robert D. Allen III, Chief Scientific Officer of Invivyd (IVVD), had 99,000 restricted stock units (RSUs convert to common shares) vest/convert on Feb 15, 2026. To satisfy tax withholding, he sold 18,189 shares on Feb 17, 2026 for a weighted average price of $1.54 (≈ $28,004) and 19,392 shares on Feb 18, 2026 for a weighted average price of $1.58 (≈ $30,597), for total gross proceeds of about $58,601. The vesting/conversion of the RSUs is reported as an exercise/conversion transaction.
Key Details
- Transaction dates and prices:
- 2026-02-15: 99,000 RSUs converted to 99,000 shares (reported as exercise/conversion).
- 2026-02-17: Sold 18,189 shares at a weighted avg $1.54 (sales executed at prices ranging $1.505–$1.590).
- 2026-02-18: Sold 19,392 shares at a weighted avg $1.58 (sales executed at prices ranging $1.550–$1.595).
- Total proceeds from open-market sales: ≈ $58,601.
- Shares owned after the transactions: not specified in the Form 4 provided.
- Notable footnotes:
- F1/F5: Each RSU equals one share; this award vests over 18 months with one‑third vesting every 6 months from Feb 15, 2025.
- F2: The open‑market sales were non‑discretionary sell‑to‑cover transactions under a Rule 10b5‑1 plan (adopted Feb 20, 2025) to satisfy tax withholding.
- F3/F4: Reported sale prices are weighted averages; the filer will provide detailed per-trade prices on request.
- Filing timeliness: Reported on Form 4 filed Feb 18, 2026 for transactions starting Feb 15, 2026 — appears timely (no late‑filing flag).
Context
- These transactions are routine for RSU vesting: RSUs converted to shares and some shares were sold to cover taxes (sell‑to‑cover). Such sell‑to‑cover sales are generally administrative and do not necessarily indicate a change in the insider’s view of the company.
- For retail investors, purchases are often more informative than routine sell‑to‑cover transactions. This filing reflects vesting and tax‑related sales rather than a discretionary sale for investment reasons.
Insider Transaction Report
Form 4
Invivyd, Inc.IVVD
Allen Robert D. III
Chief Scientific Officer
Transactions
- Exercise/Conversion
Common Stock
[F1]2026-02-15+99,000→ 152,068 total - Sale
Common Stock
[F2][F3]2026-02-17$1.54/sh−18,189$28,004→ 133,879 total - Sale
Common Stock
[F2][F4]2026-02-18$1.58/sh−19,392$30,597→ 114,487 total - Exercise/Conversion
Restricted Stock Units
[F1][F5]2026-02-15−99,000→ 102,000 total→ Common Stock (99,000 underlying)
Footnotes (5)
- [F1]Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of Invivyd, Inc. (the "Company").
- [F2]The sales reported on this Form 4 represent shares sold to satisfy the Reporting Person's tax withholding obligations upon vesting of an RSU award in non-discretionary "sell-to-cover" transactions pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on February 20, 2025.
- [F3]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $1.505 to $1.590, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company, or the staff of the U.S. Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4.
- [F4]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $1.550 to $1.595, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4.
- [F5]This RSU award vests over an eighteen-month period, with one-third of the RSUs vesting every six months following the grant date of February 15, 2025, subject to the Reporting Person's continuous service as of each vesting date.
Signature
/s/ Jill Andersen attorney-in-fact for Robert D. Allen III|2026-02-18